Heart failure & cardiomyopathies
Real-World Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry
Authors' conclusion
Use of SGLT2i increased three-fold over 2 years.
Study context
- Population
- Patients with HF with reduced ejection fraction (HFrEF) (EF <40%), no type 1 diabetes, estimated glomerular filtration rate (eGFR) <20 ml/min/1.73 m² and/or on dialysis, Swedish heart failure (HF) Registry, 1 November 2020 to 5 August 2022
- Participants
- 8,192 patients
- Outcome
- Implementation of SGLT2i over time and patient characteristics associated with their use
Methodological detailsnationwide, Swedish HF Registry
- Nationwide
- Swedish HF Registry
Main finding
As reported in the abstract
SGLT2i use
Received SGLT2i
37%
Use over time, overall
from 20.5% to 59.0%
Observational data: associations, not effects.
Further findings
SGLT2i use over time, by subgroup
- With vs without T2DM
- from 46.2% and 12.5% to 69.8% and 55.4%
- eGFR <60 vs ≥60 ml/min/1.73 m²
- from 14.7% and 22.3% to 58.0% and 59.8%
- Males vs females
- from 21.0% and 18.9% to 61.6% and 52.0%
- With vs without recent HF hospitalization
- from 24.2% and 18.0% to 60.8% and 57.7%
- Inpatients vs outpatients
- from 26.1% and 19.8% to 54.7% and 59.6%
- HF duration <6 vs ≥6 months
- from 20.2% and 21.2% to 59.2% and 58.7%
Characteristics associated with SGLT2i use (multivariable logistic regression)
- More use: male sex, recent HF hospitalization, specialized HF follow-up, lower EF, T2DM, higher education level, use of other HF/CV interventions
- Less use: older age, higher BP, AF, anaemia
Discontinuation of SGLT2i · 6 and 12 months
- Discontinuation at 6 months
- 13.1%
- Discontinuation at 12 months
- 20.0%
Original publication
Real-World Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →